OCT 19 2005

Sheet 1

TRANSDISTRUTE for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 3

Filing Dete July 7, 2005 First Nemed Inventor William Brown Art Unit Unknown 1625
Examiner Name Unknown Coring 160
Attorney Docket Number 100953-1P US

U. S. PATENT DOCUMENTS Nama of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages or Ralevant Figures Appear Document Number Publication Date Number-Kind Code² (f known) US- 2.898,339 08/04/1959 Wheeler et al. US- 4,581,171 04/08/1986 Kennis et al. US- 4.816.586 03/28/1989 Portoobese US- 4,939,137 07/03/1990 Russell et el. US-5,140,029 08/18/1992 Kennis et el. US-5,574,159 11/12/1996 Cheng et el. US-5,683,998 11/04/1997 Shibayama et al. US- 6.187.792 02/13/2001 Delorme et al. US- 6,455,545 09/24/2002 Delorme et al. US- 6,552,036 04/22/2003 Boyd et et. US- 6,556,387 04/29/2003 Misso et el. US-6,756,387 06/29/2004 Brown et al. US. US-US. US. US. US us.

FOREIGN PATENT DOCUMENTS							
Examiner initials*	No.		Publication Data	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages Or Relevant Figures Appear	П	
			MM-DD-YYYY			7*	
7		WO 93/15062	08/05/1993	The Wellcome Foundation			
1.	$\overline{}$	WO 97/23466	07/03/1997	Astra Aktiebolag			
7		WO 98/28275	07/02/1998	Astra Pherma, Inc.		Г	
1		WO 99/33806	07/08/1999	Ortho-McNeil Pharmaceutic			
1		WO 01/74804	10/11/2001	AstraZeneca AB			
1/0		WO 01/74806	10/11/2001	AstraZeneca AB			

Sprature

| Charles | Char

Translation all aductions. The register by 27 CFR 437 or 4.58. The information is required to obtain or retain a benefit by this paties, which is to fill great by the Three callection of information conferentiality approved by 15 U.S. C. 122 and 7.57 R. 14. The calculation is estimated to believe 2 towns overgone, including patienting, propering, and admitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form another upoperations for reducing the bushresh, studied as sent to the USPTO. The view of the USPTO. The view of the USPTO is the View of the USPTO. The view of the USPTO is the View of t

If you need assistence in completing the form, cell 1-800-PTO-9199 (1-800-786-9199) and select action 2.

PTC/SB/08A (07-05)

Under the Peperwork Reduction Act of 1995, no persons are required.	U.S. Patent and Trade	roved for use through 07/31/2006. OMB 0651-003 merk Office; U.S. DEPARTMENT OF COMMERCI tion unless it contains e valid OMB control number	
Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/541,664	
INFORMATION DISCLOSURE	Filing Date	July 7, 2005	
	First Named Inventor	William Brown	
STATEMENT BY APPLICANT	Art Unit	Unknown 1625	
(Use se meny sheets as necessary)	Examiner Name	LIRKOWED CO 4740764	
Sheet 2 of 3	Attorney Docket Number	100953-1P US	

U. S. PATENT DOCUMENTS						
Examiner Initiels*	Cite No.1	Number-Kind Code ^{2 (Finance)}	Publication Dete MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages or Relevant Figures Appear	
					Figures Appear	
	1	US-				
		US-				
		US-				
		US-				
		US-				
		US-	1			
	T-	US-	1			
	_	US-	1			
	_	US-				
	_	US-		***************************************		
	\vdash	US-	1			
	_	US-				
		US-	1		 	
		US-				
		US-				
		US-				
		US-				
		US-				
	-	He.	-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Pessages Or Relevant Figures Appear	Т	
		Country Code ² "Number ⁴ "Kind Code ⁶ (if Anown)	MM-DD-YYYY			7	
14		WO 02/094786	11/28/2002	AstraZeneca AB			
/		WO 02/094812	11/28/2002	AstraZeneca AB		Г	
						┡	
	_					۲	
	_		_			t	

Examine

To Address of the Considered William (white of the Considered William)

Exponential in profession considered, whether or not cliation is in conformance with IMPEP 600. Draw into through cliability in foil in porformance and not considered, which would not be implicated. Applicant's usingle cliation fraging cliation from the Considered Consid

PTOSBOSS (07-6)
Approved for use through 07/31/2006, 048 055-1003
U.S. Platent and Timedomask Office; U.S. DEPARTMENT OF COMMENCE
Under the Paysework Reduction Act of 1995, no persons are required to respond to a collection of intermetion unless a contraction as vaid Outil control number.
Compilate if Arnown

Application Numbers

I Prospective the Paysework Reduction Act of 1995, no persons are required to respond to a collection of intermetion unless a contraction as vaid Outil control number.

Application Numbers

I Prospective through 07/31/2006, 048 055-1003

Application Numbers

I Prospective through 07/31/2006, 048 057-1003

Application Numbers

I Prospective through 07/31/2006

Application Numbers

I Prospe Substitute for form 1449/PTO INFORMATION DISCLOSURE Filing Date July 7, 2005 STATEMENT BY APPLICANT First Named Inventor William Brown Art Unit Unknown /626 (Use as many sheets as necessary) Unknown Corragton Examiner Name Attorney Docket Number 100953-1P US of

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the orticle (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T²
K		BARBER, A. et al., "Antinociceptive effects of the 5-HT2 Antagonist Ritansenin in Rats: Evidence in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, p. 234-238	
K		BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, p. 359-366	
p		GREENE, T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, p. 218, 220, 232, 233, 251	
K		TAKEMORI, A.E. et al., "Selective Natrexone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, p. 239-269	
/a		WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: A Noveland its Analogues," J. Med. Chem., 2000, Vol. 43, p. 3895-3905	
Ke		ZHANG, X. et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis Opioid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, p. 5455-5463	

Examiner	11 1	Date	6	1.0
Signature	Hermand Committee	Considered	8/29	108
SEVANDARD, L	tion if enforcemental property is a post-interior to be conformance with MOCO &	O Denutine through a	totion if not in	orformance and not

[&]quot;EXAMINE: Intel® 1 relayforce considered, whether or regification is in conformance with MEPE 600. Drew line through classoff in cit. In Conformance and not considered. Includes copyoff this from with uncommunication to papietar, place a check near the Intel® (Existing league Timelation) is established. If Applicated a loss papietar, place a check near the Intel® (Existing league Timelation) is established. In Applicated a loss papietars a check near the Intel® (Existing league) Timelation) is established. In the Intel® (Intel® 100 to 100 to